251349-54-9

Usage

Uses

Used in Cancer Therapy:
2-[(2S)-1-[(1,1-dimethylethoxy)carbonyl]2-pyrrolidinyl]-4-thiazolecarboxylic acid is used as an anti-cancer agent for its ability to inhibit the progression of cancer cells. It targets the Cdc7 protein kinase, which is essential for the initiation of DNA replication, thus preventing uncontrolled cell division characteristic of cancer.
Used in Pharmaceutical Research and Development:
In the pharmaceutical industry, 2-[(2S)-1-[(1,1-dimethylethoxy)carbonyl]2-pyrrolidinyl]-4-thiazolecarboxylic acid is utilized as a key compound in the development of novel cancer treatments. Its unique structure and mechanism of action offer new avenues for the creation of drugs with potential to overcome resistance and improve patient outcomes.
Used in Drug Synthesis:
2-[(2S)-1-[(1,1-dimethylethoxy)carbonyl]2-pyrrolidinyl]-4-thiazolecarboxylic acid serves as a building block in the synthesis of other pharmaceuticals, leveraging its chemical properties to create new molecules with potential therapeutic benefits.
Further research and clinical trials are necessary to fully explore the therapeutic potential of 2-[(2S)-1-[(1,1-dimethylethoxy)carbonyl]2-pyrrolidinyl]-4-thiazolecarboxylic acid, including its efficacy, safety, and optimal delivery methods in cancer treatment.

Upstream product

• 117175-41-4 tert‐butyl (S)‐2‐carbamothioylpyrrolidine‐1‐carboxylate 
• 212009-06-8 ethyl (S)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)thiazole-4-carboxylate 
• 70138-72-6 (R)-2-carbamoylpyrrolidine-1-carboxylic acid tert-butyl ester 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 35150-07-3 (S)-tert-butyl 2-carbamoylpyrrolidine-1-carboxylate 

Downstream Products

• 1005342-46-0 (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide 
• 1005342-82-4 C₃₁H₄₁FN₄O₅S 
• 1005342-78-8 C₁₉H₂₁FN₂O₃S 

Relevant academic research and scientific papers

BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY

The present invention relates to compounds of formula (I) useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

HMG-COA REDUCTASE DEGRADATION INDUCING COMPOUND

The present invention relates HMG-CoA reductase degradation inducing compounds. Specifically, the present invention relates a bifunctional compound in which a HMG-CoA reductase binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention also relates a method for preparing the compounds, and a method for degradation of HMG-CoA reducatase using the compounds, as well as use for prevention or treatment of HMG-CoA reductase related diseases using the compounds.

MDM2 DEGRADERS AND USES THEREOF

The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.

BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY

The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of Kirsten rat sarcoma protein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Organic Compounds

The present invention is directed to a compound of the formula: or pharmaceutically acceptable salts thereof and use of such compounds for treating proliferative diseases such as cancer, in mammals.

Synthesis of novel proline-thiazole based cyclic hexa- and octapeptides

Novel proline-thiazole based cyclopeptides were produced by cyclooligomerisation of an L-proline thiazole amino acid HCl in the presence of pentafluorophenyl diphenylphosphinate (FDPP) or diphenyl phosphorazidate (DPPA).